Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Global X NASDAQ 100 Covered Call ETF (QYLD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Global X NASDAQ 100 Covered Call ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.85 (market cap $4.49B), while Global X NASDAQ 100 Covered Call ETF trades at $18.05. Which is the better fit depends on your goals.
| ACAD | QYLD | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $28.06 | $18.52 |
52-Week Low | $20.06 | $16.46 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
QYLD trades at $18.34, up 1.38% with a bullish technical signal driven by moving averages, though oscillators remain neutral. The ETF's covered-call strategy generates high monthly dividends, with recent payouts of $0.19 and $0.18, but long-term performance has lagged the Nasdaq-100's growth. News highlights concerns over NAV erosion despite the 12% yield.
Outlook: High income appeals to retirees, but capital appreciation is limited by the covered-call structure. Risks include underperformance in bull markets and concentration in tech. Investors prioritize yield over growth, yet must monitor erosion risks highlighted by financial media.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Global X NASDAQ 100 Covered Call ETF
QYLD is an ETF that follows a covered call strategy on the NASDAQ 100 Index. The fund holds a long position in the stocks of the NASDAQ 100 and simultaneously writes (sells) call options on the index. The primary goal is to generate monthly income from the option premiums. This strategy can reduce portfolio volatility and provide income, but it limits potential capital appreciation from a significant rise in the NASDAQ 100 Index.
Read more on QYLD →
